BioControl Medical Ltd. (Medimpulse AG)

www.biocontrol-medical.com

High-Tech Company

Ceased to Operate Q3/2016

TECH VERTICALS

Healthtech, Life Sciences, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	1999
Number of Employees	45
Reg. Number:	abCDe

DESCRIPTION

BioControl develops advanced active implantable medical devices for the treatment of autonomic disorders, conditions whereby the autonomic nervous system ceases to function properly, resulting in a disruption to the control of involuntary body processes. The devices enable controlled electrical stimulation of various nerves to achieve therapeutic results.

TECHNOLOGY

BioControl has developed the CardioFit(r) System, intended to effectively treat heart failure via vagus nerve stimulation. It has received the CE mark (2008) and is available in the U.S. under Investigational Device Exemption.

Products and Phases

Product	Phase
CardioFit(TM)	CE Approved
The brain helps to control the function of the heart through two branches. The sympathetic branch activates the “fight or flight” response during stress, increasing heart rate and blood pressure. The parasympathetic branch has a calming effect on the heart through signals carried by the vagus nerve. Normally, the two branches are in “balance”. In heart failure, however, there is an imbalance. The sympathetic branch is in overdrive while the parasympathetic branch is underactive. Some heart failure medications help to “slow down” the sympathetic branch, but currently there are no proven treatments that help the underactive parasympathetic branch. The CardioFit® system from BioControl Medical is the first device designed to increase the effect of the parasympathetic branch. The goal is to bring better balance to the heart so that heart failure symptoms are alleviated and heart failure deterioration is reversed.
FitNeS	CE Approved
The FitNeS system consists of an implanted stimulator and stimulation lead. The two parts work together to deliver electrical signals through the left vagus nerve, running from the brainstem through the neck and to the chest and abdomen, to calm the overly excited nerve cells in the brain. The system also aims to minimize the activation of non-related nerve fibers and the surrounding tissues. The FitNeS system was developed to offer a new treatment option for refractory epilepsy patients while delivering improvements over existing vagus nerve stimulation devices. In addition to its potential to increase stimulation efficacy and minimize side effects, the FitNeS system was designed to employ lower currents, , reduce current leakage through improved cuff isolation, and allow for safe and easy explant of the electrode if required. The FitNeS system has CE marking and is available in Europe through CerebralRx, which holds exclusive rights to BioControl Medical's platform vagus nerve stimulation technology for treating neurological disorders. FitNeS is not available in the United States. The FitNeS system was developed to offer a new treatment option for refractory epilepsy patients while delivering improvements over existing vagus nerve stimulation devices. In addition to its potential to increase stimulation efficacy and minimize side effects, the FitNeS system was designed to employ lower currents, minimize nerve damage through a unique nerve electrode interface, reduce current leakage through improved cuff isolation, and allow for safe and easy explant of the electrode if required. The FitNeS system has CE marking and is available in Europe through CerebralRx, which holds exclusive rights to BioControl Medical’s platform vagus nerve stimulation technology for treating neurological disorders. FitNeS is not available in the United States.

	TARGET MARKETS
	Patients with congestive heart failures. Patients with neurological disorders.

	BUSINESS MODEL
	B2C

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
578995C6-1F7A-E111-AC59-00155D32A403		CerebralRx Ltd.		Ceased
3FDA57F6-1F7A-E111-AC59-00155D32A403	Spin-off	BioControl Medical Ltd. (Medimpulse AG)	CerebralRx Ltd.	Ceased

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm

CONTACT INFO

Expand / Collapse All

Main Address: Yehud-Monosson, Israel

Address	3 Geron St.
POB	2713
City	Yehud-Monosson
Country	Israel
Zip	5621717

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: New Hope, United States

Address	9220 Bass Lake Rd. , Suite 255
City	New Hope
State/Province	MN
Country	United States
Zip	55428

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Offer Erlichman	VP, Finance	SOSA (VP, Finance)
Mr. Yossi Gross	Co-Founder
Mr. Boaz Lifschitz	Co-Founder
Mr. Eyal Lifschitz	Co-Founder	NGT (Investment Committee Member)

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Fifth Round

May. 24, 2010

R&D

abCDe

Other

Mar. 01, 2010

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe	Transferred from Biomedical Investments; Holds 3% of the company

Fourth Round

Jun. 01, 2005

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Holds 18% of the company
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe

Third Round

Jun. 01, 2004

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe

Second Round

Nov. 25, 2001

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Other	abCDe

First Round

Jun. 01, 2000

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe

Last Updated:	abCDe
IVC Number:	abCDe